secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001493152-24-011514
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity Q4 net loss $18.8M; FY net loss $63.8M; cash into H1 2026; VIKTORIA-1 topline data H2 2024
--------------------------------------------------------------------------------

- Net loss Q4 2023 $18.8M ($0.65 loss per share) vs $11.6M ($0.69) in Q4 2022.
- Full year 2023 net loss $63.8M ($2.69 per share) vs $40.4M ($2.64) in 2022.
- Raised $65M from equity sale; cash expected to fund operations into first half of 2026.
- Phase 3 VIKTORIA-1 trial on track to report topline data for PIK3CA wild type subgroup H2 2024.
- First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC in February 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000149315224011514/0001493152-24-011514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000149315224011514/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer